ValueAct Capital Discloses Sale of Shares of Valeant Pharmaceuticals International, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St futures retreat as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Qualcomm secures long-term Apple patent deal, easing revenue fears
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Valeant Pharma (VRX) Active Early Amid ValueAct Stock Sale
June 11, 2015 9:43 AM EDTValeant Pharma (NYSE: VRX) shares are trading to the upside early Thursday morning following disclosure of a recent insider trade.
Ahead of the opening bell, ValueAct Capital Management, L.P. announced that it has sold 4.2 million shares of Valeant in... More
ValueAct Sold 4.2M Valeant Pharma (VRX) Shares
June 11, 2015 9:29 AM EDTValueAct Capital Management, L.P. announced that it has sold 4.2 million shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) in brokers' transactions on the NYSE.
ValueAct Capital's CEO Jeffrey W. Ubben said: "Mike Pearson and the Valeant team's exceptional performance have once... More
